On December 20, 2020, CBP-1008 Phase Ib trial investigator meeting was held in Beijing, during which heated discussions on clinica...
On October 16, 2020, CBP-1008, a bi-engaging ligand-mediated selective targeting drug conjugate developed by Coherent Biopharma, g...
On November 4, 2020, Notice on Approval for Drug Clinical Trial was issued by NMPA for CBP-1018, the second bi-engaging...
On July 10, 2020, New Drug R&D Center of Coherent Biopharma (Suzhou) Co., Ltd, hosted a celebration for its relocation at Jinj...
June 14, 2019 witnessed the signing ceremony of “1+N” cooperation projects in biopharmaceuticals hosted by Suzhou Municip...
In October 2018, Coherent Biopharma completed its Series A2 fundraising of 20 million USD led by 6 Dimensions Capital to facilitat...